Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early oxybutynin treatment for boys with posterior urethral valves
2019-004417-13Phase 2Active
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of oxybutynin in congenital posterior urethral valves (PUV) (2 arms), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoints: Composite urodynamic success at 9 months and Pharmacokinetic safety of oxybutynin. Started Jan 2020; status: active.
02
Drugs
oxybutynin
03
Conditions
congenital posterior urethral valves (PUV)
Beyond the preview
Go deeper on 2019-004417-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004417-13.